Jeannie Tran1, Emmeline Ayers2, Joe Verghese1,2, Matthew K Abramowitz3. 1. Departments of Medicine and. 2. Neurology, Albert Einstein College of Medicine, Bronx, New York. 3. Departments of Medicine and matthew.abramowitz@einstein.yu.edu.
Abstract
BACKGROUND AND OBJECTIVES: Older adults with CKD are at high risk of falls and disability. It is not known whether gait abnormalities contribute to this risk. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Quantitative and clinical gait assessments were performed in 330 nondisabled community-dwelling adults aged ≥65 years. CKD was defined as an eGFR <60 ml/min per 1.73 m2. Cox proportional hazards models were created to examine fall risk. RESULTS: A total of 41% (n=134) of participants had CKD. In addition to slower gait speed, participants with CKD had gait cycle abnormalities including shorter stride length and greater time in the stance and double-support phases. Among people with CKD, lower eGFR was independently associated with the severity of gait cycle abnormalities (per 10 ml/min per 1.73 m2 lower eGFR: 3.6 cm [95% confidence interval (95% CI), 1.4 to 5.8] shorter stride length; 0.7% [95% CI, 0.3 to 1.0] less time in swing phase; 1.1% [95% CI, 0.5 to 1.7] greater time in double-support phase); these abnormalities mediated the association of lower eGFR with slower gait speed. On clinical gait exam, consistent with the quantitative abnormalities, short steps and marked swaying or loss of balance were more common among participants with CKD, yet most had no identifiable gait phenotype. A gait phenotype defined by any of these abnormal signs was associated with higher risk of falls among participants with CKD: compared with people without CKD and without the gait phenotype, the adjusted hazard ratio was 1.72 (95% CI, 1.06 to 2.81) for those with CKD and the phenotype; in comparison, the adjusted hazard ratio was 0.71 (95% CI, 0.40 to 1.25) for people with CKD but without the phenotype (P value for interaction of CKD status and gait phenotype =0.01). CONCLUSIONS: CKD in older adults is associated with quantitative gait abnormalities, which clinically manifest in a gait phenotype that is associated with fall risk.
BACKGROUND AND OBJECTIVES: Older adults with CKD are at high risk of falls and disability. It is not known whether gait abnormalities contribute to this risk. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Quantitative and clinical gait assessments were performed in 330 nondisabled community-dwelling adults aged ≥65 years. CKD was defined as an eGFR <60 ml/min per 1.73 m2. Cox proportional hazards models were created to examine fall risk. RESULTS: A total of 41% (n=134) of participants had CKD. In addition to slower gait speed, participants with CKD had gait cycle abnormalities including shorter stride length and greater time in the stance and double-support phases. Among people with CKD, lower eGFR was independently associated with the severity of gait cycle abnormalities (per 10 ml/min per 1.73 m2 lower eGFR: 3.6 cm [95% confidence interval (95% CI), 1.4 to 5.8] shorter stride length; 0.7% [95% CI, 0.3 to 1.0] less time in swing phase; 1.1% [95% CI, 0.5 to 1.7] greater time in double-support phase); these abnormalities mediated the association of lower eGFR with slower gait speed. On clinical gait exam, consistent with the quantitative abnormalities, short steps and marked swaying or loss of balance were more common among participants with CKD, yet most had no identifiable gait phenotype. A gait phenotype defined by any of these abnormal signs was associated with higher risk of falls among participants with CKD: compared with people without CKD and without the gait phenotype, the adjusted hazard ratio was 1.72 (95% CI, 1.06 to 2.81) for those with CKD and the phenotype; in comparison, the adjusted hazard ratio was 0.71 (95% CI, 0.40 to 1.25) for people with CKD but without the phenotype (P value for interaction of CKD status and gait phenotype =0.01). CONCLUSIONS: CKD in older adults is associated with quantitative gait abnormalities, which clinically manifest in a gait phenotype that is associated with fall risk.
Authors: Joe Verghese; Mindy J Katz; Carol A Derby; Gail Kuslansky; Charles B Hall; Richard B Lipton Journal: Age Ageing Date: 2004-11 Impact factor: 10.668
Authors: Linda F Fried; Jung Sun Lee; Michael Shlipak; Glenn M Chertow; Christie Green; Jingzhong Ding; Tamara Harris; Anne B Newman Journal: J Am Geriatr Soc Date: 2006-05 Impact factor: 5.562
Authors: Joe Verghese; Richard B Lipton; Charles B Hall; Gail Kuslansky; Mindy J Katz; Herman Buschke Journal: N Engl J Med Date: 2002-11-28 Impact factor: 91.245
Authors: Joe Verghese; Aaron LeValley; Charles B Hall; Mindy J Katz; Anne F Ambrose; Richard B Lipton Journal: J Am Geriatr Soc Date: 2006-02 Impact factor: 5.562
Authors: Brandon Cohen; Samhitha Munugoti; Sonia Kotwani; Lovepreet S Randhawa; Solomon Dalezman; Antonio C Elters; Kate Nam; Jose S Ibarra; Sandheep Venkataraman; William Paredes; Nitin Ohri; Matthew K Abramowitz Journal: Kidney360 Date: 2022-07-13
Authors: Melanie J Koren; Helena M Blumen; Emmeline I Ayers; Joe Verghese; Matthew K Abramowitz Journal: Clin J Am Soc Nephrol Date: 2021-04-06 Impact factor: 8.237
Authors: Atsumi Kimura; William Paredes; Rima Pai; Hina Farooq; Rupinder S Buttar; Matthew Custodio; Samhitha Munugoti; Sonia Kotwani; Lovepreet S Randhawa; Solomon Dalezman; Antonio C Elters; Kate Nam; Jose S Ibarra; Sandheep Venkataraman; Matthew K Abramowitz Journal: BMC Nephrol Date: 2022-02-22 Impact factor: 2.388
Authors: Andrea Corsonello; Regina Roller-Wirnsberger; Gerhard Wirnsberger; Johan Ärnlöv; Axel C Carlsson; Lisanne Tap; Francesco Mattace-Raso; Francesc Formiga; Rafael Moreno-Gonzalez; Christian Weingart; Cornel Sieber; Tomasz Kostka; Agnieszka Guligowska; Pedro Gil; Sara Lainez Martinez; Rada Artzi-Medvedik; Itshak Melzer; Fabrizia Lattanzio Journal: J Clin Med Date: 2020-01-21 Impact factor: 4.241